首页 > 最新文献

Current Urology最新文献

英文 中文
Transcription factor E3 renal cell carcinoma presenting as secondary hypertension. 转录因子E3肾细胞癌表现为继发性高血压。
IF 1.6 4区 医学 Q4 UROLOGY & NEPHROLOGY Pub Date : 2023-03-01 DOI: 10.1097/CU9.0000000000000108
Alain Mwamba Mukendi, Gerald Tatenda Mataruka, Ramesh Nadimpalli, Tshisola Miji Kasapato

Microphthalmia-associated transcription factor family (transcription factor E3 or transcription factor EB) translocation renal cell carcinomas (RCCs) are rare neoplasms. These renal neoplasms can be either asymptomatic and incidentally discovered on imaging or symptomatic, with the most common presenting symptoms being hematuria, pain, and abdominal mass, or paraneoplastic event. In conventional RCCs, hypertension is considered a risk factor and a possible paraneoplastic event, whereas, in translocation RCCs, prior exposure to cytotoxic chemotherapy is the only known risk factor, and hypertension as an isolated associated paraneoplastic event has never been reported. Interestingly, hypertension as the only presenting symptom in RCC is extremely rare. We report a case of transcription factor E3 positive RCC in a young adult presenting only with hypertension that normalized after radical nephrectomy. To the best of our knowledge, this is the first reported case of hypertension secondary to microphthalmia-associated transcription translocation RCC.

小眼相关转录因子家族(转录因子E3或转录因子EB)易位性肾细胞癌(RCCs)是一种罕见的肿瘤。这些肾脏肿瘤可以是无症状的,在影像学上偶然发现的,也可以是有症状的,最常见的症状是血尿、疼痛、腹部肿块或副肿瘤事件。在传统的rcc中,高血压被认为是一个危险因素和可能的副肿瘤事件,然而,在易位性rcc中,先前暴露于细胞毒性化疗是唯一已知的危险因素,并且高血压作为一个孤立的相关副肿瘤事件从未报道过。有趣的是,高血压作为肾小细胞癌的唯一症状是非常罕见的。我们报告一例转录因子E3阳性的RCC在一个年轻的成年人只表现为高血压,在根治性肾切除术后正常化。据我们所知,这是首例报道的小眼相关转录易位RCC继发高血压的病例。
{"title":"Transcription factor E3 renal cell carcinoma presenting as secondary hypertension.","authors":"Alain Mwamba Mukendi,&nbsp;Gerald Tatenda Mataruka,&nbsp;Ramesh Nadimpalli,&nbsp;Tshisola Miji Kasapato","doi":"10.1097/CU9.0000000000000108","DOIUrl":"https://doi.org/10.1097/CU9.0000000000000108","url":null,"abstract":"<p><p>Microphthalmia-associated transcription factor family (transcription factor E3 or transcription factor EB) translocation renal cell carcinomas (RCCs) are rare neoplasms. These renal neoplasms can be either asymptomatic and incidentally discovered on imaging or symptomatic, with the most common presenting symptoms being hematuria, pain, and abdominal mass, or paraneoplastic event. In conventional RCCs, hypertension is considered a risk factor and a possible paraneoplastic event, whereas, in translocation RCCs, prior exposure to cytotoxic chemotherapy is the only known risk factor, and hypertension as an isolated associated paraneoplastic event has never been reported. Interestingly, hypertension as the only presenting symptom in RCC is extremely rare. We report a case of transcription factor E3 positive RCC in a young adult presenting only with hypertension that normalized after radical nephrectomy. To the best of our knowledge, this is the first reported case of hypertension secondary to microphthalmia-associated transcription translocation RCC.</p>","PeriodicalId":39147,"journal":{"name":"Current Urology","volume":"17 1","pages":"58-61"},"PeriodicalIF":1.6,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/c9/5d/curr-urol-17-58.PMC10487286.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10569902","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A rare triple concurrence of ureteric calculus and renal cell carcinoma in a horseshoe kidney. 一个罕见的马蹄肾输尿管结石和肾细胞癌三重并发。
IF 1.6 4区 医学 Q4 UROLOGY & NEPHROLOGY Pub Date : 2023-03-01 DOI: 10.1097/CU9.0000000000000179
Kale Munien, Joshua Winston, Nicholas Davies

Horseshoe kidney is a rare anatomical variant with low clinical morbidity. However, the characteristic shape of horseshoe kidney causes significant anomalies within the vascular and collecting systems. This complicates the diagnosis and management of coexisting pathologies within the kidneys. Here, we report a rare case of concurrent diagnoses of ipsilateral ureteric calculus and renal cell carcinoma within a horseshoe kidney and describe the subsequent management rationale based on the current literature.

马蹄肾是一种罕见的解剖变异,临床发病率低。然而,马蹄肾的特殊形状在血管和收集系统内引起明显的异常。这使肾脏内共存病理的诊断和处理复杂化。在此,我们报告一例罕见的马蹄肾内同侧输尿管结石和肾细胞癌同时诊断的病例,并根据目前的文献描述后续的治疗原理。
{"title":"A rare triple concurrence of ureteric calculus and renal cell carcinoma in a horseshoe kidney.","authors":"Kale Munien,&nbsp;Joshua Winston,&nbsp;Nicholas Davies","doi":"10.1097/CU9.0000000000000179","DOIUrl":"https://doi.org/10.1097/CU9.0000000000000179","url":null,"abstract":"<p><p>Horseshoe kidney is a rare anatomical variant with low clinical morbidity. However, the characteristic shape of horseshoe kidney causes significant anomalies within the vascular and collecting systems. This complicates the diagnosis and management of coexisting pathologies within the kidneys. Here, we report a rare case of concurrent diagnoses of ipsilateral ureteric calculus and renal cell carcinoma within a horseshoe kidney and describe the subsequent management rationale based on the current literature.</p>","PeriodicalId":39147,"journal":{"name":"Current Urology","volume":"17 1","pages":"41-44"},"PeriodicalIF":1.6,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/d0/d1/curr-urol-17-41.PMC10487285.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10224047","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Ureteroscopy during pregnancy: Outcomes and lessons learned over 4 decades at a tertiary center in Norway. 妊娠期间输尿管镜检查:挪威一家三级中心40多年来的结果和经验教训。
IF 1.6 4区 医学 Q4 UROLOGY & NEPHROLOGY Pub Date : 2023-03-01 DOI: 10.1097/CU9.0000000000000157
Patrick Juliebø-Jones, Christian Beisland, Peder Gjengstø, Stephen Baug, Øyvind Ulvik

Background: The management of suspected kidney stone disease in pregnancy is challenging. In cases of persistent flank pain and where investigations may have rendered equivocal results, ureteroscopy (URS) is a recognized diagnostic and therapeutic intervention. This study aimed to investigate the safety and outcomes associated with performing URS during pregnancy, as the technique has evolved over the past 4 decades at our center.

Materials and methods: We performed a retrospective analysis of pregnant patients who underwent URS at our tertiary center between 1984 and 2022. Outcomes of interest included anesthetic approach, operative time, hospital stay, and complications.

Results: Eighty-seven pregnant patients underwent 96 URS procedures, and 60% (n = 57) of these procedures were performed during the third trimester. Overall, 58% (n = 56) of the procedures were achieved with local anesthesia and light sedation. During the most recent decade, the latter was successfully carried out in 97% of the procedures, with the remainder occurring under spinal anesthesia as per patient choice. Overall, 57% (n = 50) of the whole study group had ureteral calculi found at the time of surgery and in 88% (n = 44) of these cases, fragmentation/extraction was performed. The remainder had insertion of ureteral stent with definitive clearance deferred until postpartum. Mean operative time and postprocedure hospital stay was 33 minutes (range, 7-100 minutes) and 2.2 days (range, 0-16 days), respectively. The overall intraoperative and postoperative complication rates were 2% and 11%, respectively. During the final decade, the latter improved to 6% and all adverse events were minor (Clavien I/II), with the exception of a single case. Regarding exit strategy, ureteral stent was placed in 42% (n = 40) of the procedures, 23% (n = 22) had ureteral catheter inserted, and the remainder (35%, n = 34) had none.

Conclusions: Ureteroscopy can be safely performed during pregnancy using anesthetic approach with local anesthesia and light sedation. Development of a local protocol and multidisciplinary management algorithm are instrumental in enabling the delivery of such a service.

背景:妊娠期疑似肾结石的处理具有挑战性。在持续的侧腹疼痛的情况下,如果调查结果模棱两可,输尿管镜检查(URS)是公认的诊断和治疗干预措施。在过去的40年里,我们中心的泌尿外科技术不断发展,本研究旨在调查妊娠期泌尿外科手术的安全性和相关结果。材料和方法:我们对1984年至2022年间在我们三级中心接受尿路手术的孕妇进行了回顾性分析。结果包括麻醉入路、手术时间、住院时间和并发症。结果:87例孕妇接受了96次URS手术,其中60% (n = 57)的手术在妊娠晚期进行。总的来说,58% (n = 56)的手术是在局部麻醉和轻度镇静下完成的。在最近的十年中,后者在97%的手术中成功进行,其余的手术根据患者的选择在脊髓麻醉下进行。总体而言,整个研究组中57% (n = 50)的患者在手术时发现输尿管结石,其中88% (n = 44)的患者进行了碎裂/拔除。其余患者则接受输尿管支架置入,最终清除延迟至产后。平均手术时间和术后住院时间分别为33分钟(范围7-100分钟)和2.2天(范围0-16天)。术中和术后并发症发生率分别为2%和11%。在最后十年中,后者提高到6%,所有不良事件都是轻微的(Clavien I/II),除了一个病例。关于退出策略,42% (n = 40)的手术放置了输尿管支架,23% (n = 22)的手术插入了输尿管导管,其余的(35%,n = 34)没有。结论:妊娠期输尿管镜检查采用局麻加轻镇静的麻醉入路是安全的。本地协议和多学科管理算法的开发有助于实现这种服务的交付。
{"title":"Ureteroscopy during pregnancy: Outcomes and lessons learned over 4 decades at a tertiary center in Norway.","authors":"Patrick Juliebø-Jones,&nbsp;Christian Beisland,&nbsp;Peder Gjengstø,&nbsp;Stephen Baug,&nbsp;Øyvind Ulvik","doi":"10.1097/CU9.0000000000000157","DOIUrl":"https://doi.org/10.1097/CU9.0000000000000157","url":null,"abstract":"<p><strong>Background: </strong>The management of suspected kidney stone disease in pregnancy is challenging. In cases of persistent flank pain and where investigations may have rendered equivocal results, ureteroscopy (URS) is a recognized diagnostic and therapeutic intervention. This study aimed to investigate the safety and outcomes associated with performing URS during pregnancy, as the technique has evolved over the past 4 decades at our center.</p><p><strong>Materials and methods: </strong>We performed a retrospective analysis of pregnant patients who underwent URS at our tertiary center between 1984 and 2022. Outcomes of interest included anesthetic approach, operative time, hospital stay, and complications.</p><p><strong>Results: </strong>Eighty-seven pregnant patients underwent 96 URS procedures, and 60% (<i>n</i> = 57) of these procedures were performed during the third trimester. Overall, 58% (n = 56) of the procedures were achieved with local anesthesia and light sedation. During the most recent decade, the latter was successfully carried out in 97% of the procedures, with the remainder occurring under spinal anesthesia as per patient choice. Overall, 57% (n = 50) of the whole study group had ureteral calculi found at the time of surgery and in 88% (n = 44) of these cases, fragmentation/extraction was performed. The remainder had insertion of ureteral stent with definitive clearance deferred until postpartum. Mean operative time and postprocedure hospital stay was 33 minutes (range, 7-100 minutes) and 2.2 days (range, 0-16 days), respectively. The overall intraoperative and postoperative complication rates were 2% and 11%, respectively. During the final decade, the latter improved to 6% and all adverse events were minor (Clavien I/II), with the exception of a single case. Regarding exit strategy, ureteral stent was placed in 42% (n = 40) of the procedures, 23% (n = 22) had ureteral catheter inserted, and the remainder (35%, n = 34) had none.</p><p><strong>Conclusions: </strong>Ureteroscopy can be safely performed during pregnancy using anesthetic approach with local anesthesia and light sedation. Development of a local protocol and multidisciplinary management algorithm are instrumental in enabling the delivery of such a service.</p>","PeriodicalId":39147,"journal":{"name":"Current Urology","volume":"17 1","pages":"7-12"},"PeriodicalIF":1.6,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/5e/fd/curr-urol-17-07.PMC10487287.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10275564","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 8
Management of urolithiasis in pregnancy. 妊娠期尿路结石的处理。
IF 0.9 4区 医学 Q4 UROLOGY & NEPHROLOGY Pub Date : 2023-03-01 Epub Date: 2023-02-16 DOI: 10.1097/CU9.0000000000000181
Kimberley Chan, Taner Shakir, Omar El-Taji, Amit Patel, John Bycroft, Chou Phay Lim, Nikhil Vasdev

Urolithiasis is the most common cause of nonobstetric abdominal pain, resulting in 1.7 admissions per 1000 deliveries. Urolithiasis most commonly occurs in the second and third trimesters, with an incidence between 1:125 and 1:2000. Acute urinary system obstructions are challenging to manage in obstetric patients because they contribute to physiological and anatomical changes that result in pathological outcomes. The restricted use of computed tomography in diagnosing and managing urolithiasis is particularly challenging. In addition, a prompt diagnosis is required because the presence of renal calculi during pregnancy increases the risk of fulminating sepsis and preterm delivery. Affected pregnancies are conservatively managed; however, 1 in 4 requires surgical intervention. Indications for surgical interventions are complex and range from nephrostomy insertion to empirical stent placement or ureteroscopy. Therefore, a multidisciplinary approach is required to optimize patient care. The diagnosis and management of urolithiasis in pregnancy are complex. We reviewed the role, safety, advantages and disadvantages of diagnostic tests and treatment used to manage acute urinary obstructions in pregnancy.

泌尿系结石是非产科腹痛最常见的原因,每 1000 例分娩中就有 1.7 例入院治疗。泌尿系结石最常发生在第二和第三孕期,发病率在 1:125 到 1:2000 之间。急性泌尿系统梗阻对产科病人的治疗具有挑战性,因为它会导致生理和解剖上的变化,从而导致病理结果。在诊断和处理尿路结石时,计算机断层扫描的使用受到限制,这尤其具有挑战性。此外,由于妊娠期出现肾结石会增加脓毒症和早产的风险,因此需要及时诊断。受影响的孕妇可采取保守治疗,但四分之一的孕妇需要手术治疗。手术干预的指征很复杂,从插入肾造瘘管到经验性支架置入或输尿管镜检查,不一而足。因此,需要采用多学科方法来优化患者护理。妊娠期尿路结石的诊断和治疗非常复杂。我们回顾了用于治疗妊娠期急性尿路梗阻的诊断检查和治疗方法的作用、安全性和优缺点。
{"title":"Management of urolithiasis in pregnancy.","authors":"Kimberley Chan, Taner Shakir, Omar El-Taji, Amit Patel, John Bycroft, Chou Phay Lim, Nikhil Vasdev","doi":"10.1097/CU9.0000000000000181","DOIUrl":"10.1097/CU9.0000000000000181","url":null,"abstract":"<p><p>Urolithiasis is the most common cause of nonobstetric abdominal pain, resulting in 1.7 admissions per 1000 deliveries. Urolithiasis most commonly occurs in the second and third trimesters, with an incidence between 1:125 and 1:2000. Acute urinary system obstructions are challenging to manage in obstetric patients because they contribute to physiological and anatomical changes that result in pathological outcomes. The restricted use of computed tomography in diagnosing and managing urolithiasis is particularly challenging. In addition, a prompt diagnosis is required because the presence of renal calculi during pregnancy increases the risk of fulminating sepsis and preterm delivery. Affected pregnancies are conservatively managed; however, 1 in 4 requires surgical intervention. Indications for surgical interventions are complex and range from nephrostomy insertion to empirical stent placement or ureteroscopy. Therefore, a multidisciplinary approach is required to optimize patient care. The diagnosis and management of urolithiasis in pregnancy are complex. We reviewed the role, safety, advantages and disadvantages of diagnostic tests and treatment used to manage acute urinary obstructions in pregnancy.</p>","PeriodicalId":39147,"journal":{"name":"Current Urology","volume":"17 1","pages":"1-6"},"PeriodicalIF":0.9,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/16/57/curr-urol-17-01.PMC10487296.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10221801","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Aquablation in men with benign prostate hyperplasia: A systematic review and meta-analysis. 男性良性前列腺增生的水消融:一项系统回顾和荟萃分析。
IF 1.6 4区 医学 Q4 UROLOGY & NEPHROLOGY Pub Date : 2023-03-01 DOI: 10.1097/CU9.0000000000000122
David C Chen, Liang Qu, Howard Webb, Kirby Qin, Bodie Chislett, Alan Xue, Sari Khaleel, Manuel De Jesus Escano, Eric Chung, Ahmed Adam, Damien Bolton, Marlon Perera

Objective: The aim of the study is to investigate improvements in lower urinary tract symptoms in men with benign prostatic hyperplasia (BPH) treated with prostatic Aquablation.

Materials and methods: We performed a literature search of clinical trials using the MEDLINE, Embase, and Cochrane Library databases and retrieved published works on Aquablation for the treatment of BPH up to August 2021. Unpublished works, case reports, conference proceedings, editorial comments, and letters were excluded. Risk of bias was assessed using the ROBINS-I tool. Raw means and mean differences were meta-analyzed to produce summary estimates for pre- versus post-International Prostate Symptom Scores, maximum flow rate, and male sexual health questionnaire value changes. An inverse-variance weighted random effects model was used.

Results: Seven studies were included in this review (n = 551 patients) that evaluated various urological parameters. At 3 months, the International Prostate Symptom Scores raw mean difference from baseline was -16.475 (95% confidence interval [CI], -15.264 to -17.686; p < 0.001), with improvements sustained for 12 months. Similarly, maximum flow rate improved by +1.96 (95% CI, 10.015 to 11.878; p < 0.001) from pre to 3 months postoperatively. In addition, the male sexual health questionnaire change pooled effect size was -0.55 (95% CI, -1.621 to 0.531; p = 0.321) from preintervention to postintervention at 3 months. Meta-analyses of some outcomes showed large statistical heterogeneity or evidence of publication bias.

Conclusions: Aquablation seems to improve lower urinary tract symptoms in men with BPH while providing relatively preserved sexual function. Further research is required to confirm these preliminary results.

目的:探讨前列腺水消融治疗男性良性前列腺增生(BPH)患者下尿路症状的改善情况。材料和方法:我们使用MEDLINE、Embase和Cochrane图书馆数据库进行了临床试验的文献检索,并检索了截至2021年8月关于水消融治疗BPH的已发表作品。未发表的作品、病例报告、会议记录、编辑评论和信件被排除在外。使用ROBINS-I工具评估偏倚风险。对原始均值和均值差异进行荟萃分析,得出国际前列腺症状评分前后、最大流速和男性性健康问卷值变化的汇总估计。采用反方差加权随机效应模型。结果:本综述纳入了7项研究(n = 551例患者),评估了各种泌尿系统参数。3个月时,国际前列腺症状评分与基线的原始平均差值为-16.475(95%可信区间[CI], -15.264至-17.686;P < 0.001),改善持续12个月。同样,最大流量提高了+1.96 (95% CI, 10.015至11.878;P < 0.001)。此外,男性性健康问卷变化汇总效应量为-0.55 (95% CI, -1.621 ~ 0.531;P = 0.321)。对一些结果的荟萃分析显示了较大的统计异质性或发表偏倚的证据。结论:水消融似乎可以改善BPH患者的下尿路症状,同时提供相对保留的性功能。需要进一步的研究来证实这些初步结果。
{"title":"Aquablation in men with benign prostate hyperplasia: A systematic review and meta-analysis.","authors":"David C Chen,&nbsp;Liang Qu,&nbsp;Howard Webb,&nbsp;Kirby Qin,&nbsp;Bodie Chislett,&nbsp;Alan Xue,&nbsp;Sari Khaleel,&nbsp;Manuel De Jesus Escano,&nbsp;Eric Chung,&nbsp;Ahmed Adam,&nbsp;Damien Bolton,&nbsp;Marlon Perera","doi":"10.1097/CU9.0000000000000122","DOIUrl":"https://doi.org/10.1097/CU9.0000000000000122","url":null,"abstract":"<p><strong>Objective: </strong>The aim of the study is to investigate improvements in lower urinary tract symptoms in men with benign prostatic hyperplasia (BPH) treated with prostatic Aquablation.</p><p><strong>Materials and methods: </strong>We performed a literature search of clinical trials using the MEDLINE, Embase, and Cochrane Library databases and retrieved published works on Aquablation for the treatment of BPH up to August 2021. Unpublished works, case reports, conference proceedings, editorial comments, and letters were excluded. Risk of bias was assessed using the ROBINS-I tool. Raw means and mean differences were meta-analyzed to produce summary estimates for pre- versus post-International Prostate Symptom Scores, maximum flow rate, and male sexual health questionnaire value changes. An inverse-variance weighted random effects model was used.</p><p><strong>Results: </strong>Seven studies were included in this review (n = 551 patients) that evaluated various urological parameters. At 3 months, the International Prostate Symptom Scores raw mean difference from baseline was -16.475 (95% confidence interval [CI], -15.264 to -17.686; <i>p</i> < 0.001), with improvements sustained for 12 months. Similarly, maximum flow rate improved by +1.96 (95% CI, 10.015 to 11.878; <i>p</i> < 0.001) from pre to 3 months postoperatively. In addition, the male sexual health questionnaire change pooled effect size was -0.55 (95% CI, -1.621 to 0.531; <i>p =</i> 0.321) from preintervention to postintervention at 3 months. Meta-analyses of some outcomes showed large statistical heterogeneity or evidence of publication bias.</p><p><strong>Conclusions: </strong>Aquablation seems to improve lower urinary tract symptoms in men with BPH while providing relatively preserved sexual function. Further research is required to confirm these preliminary results.</p>","PeriodicalId":39147,"journal":{"name":"Current Urology","volume":"17 1","pages":"68-76"},"PeriodicalIF":1.6,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/6a/c2/curr-urol-17-68.PMC10487298.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10275568","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
The efficacy and safety of one-stage endoscopy combined with intrarenal surgery (mini-nephrostomy tract) in the prone split-leg position for complex renal calculi. 一期内窥镜联合肾内手术(小肾造瘘道)治疗复杂肾结石俯卧劈腿位的疗效和安全性。
IF 1.6 4区 医学 Q4 UROLOGY & NEPHROLOGY Pub Date : 2023-03-01 DOI: 10.1097/CU9.0000000000000148
Kai Yu, Zhebin Du, Hanqing Xuan, Yang Cao, Hai Zhong, Fangzhou Li, Qi Chen

Background: The goal of this study was to determine the safety and efficacy of endoscopic combined intrarenal surgery (ECIRS) performed in the prone split-leg position for the treatment of complex renal stones.

Materials and methods: A mature ECIRS protocol was designed. Retrospective analysis was conducted of medical records between January 2020 and December 2021 of patients with complex renal stones at one center who underwent ECIRS by 2 skilled surgeons using retrograde flexible ureteroscopy and mini-percutaneous nephrolithotomy in the prone split-leg position.

Results: A total of 44 patients were included in this study. Mean stone size was 26.1 ± 12.7 mm, and the number of calyces involved was 4.36 ± 2.09. Mean operative time was 71.1 ± 21.8 minutes. Postoperative decline in hemoglobin was 15.8 ± 9.8 g/L. Seventy-five percent of patients achieved stone-free status. The mean number of residual stones was 2.8 ± 2.3, and the mean residual stone size was 10.30 ± 4.76 mm. Six patients (13.6%) developed postoperative complications, including 4 with fever during the first 2 days postoperatively and 2 patients with transient postoperative pain. No patients developed severe complications.

Conclusions: Endoscopic combined intrarenal surgery in the prone split-leg position can be performed safely by experienced surgeons using retrograde flexible ureteroscopy in conjunction with mini-percutaneous nephrolithotomy as a successful technique for the treatment of complex renal stones.

背景:本研究的目的是确定内窥镜联合肾内手术(ECIRS)在俯卧劈腿位治疗复杂肾结石的安全性和有效性。材料与方法:设计了成熟的ECIRS方案。回顾性分析了2020年1月至2021年12月在某中心由2名熟练外科医生采用逆行输尿管软镜和微型经皮肾镜取石术进行ECIRS的复杂肾结石患者的病历。结果:本研究共纳入44例患者。结石的平均大小为26.1±12.7 mm,受累的萼数为4.36±2.09个。平均手术时间71.1±21.8分钟。术后血红蛋白下降15.8±9.8 g/L。75%的患者达到了无结石状态。平均残余结石数为2.8±2.3颗,平均残余结石大小为10.30±4.76 mm。6例(13.6%)出现术后并发症,其中4例术后2天发热,2例术后一过性疼痛。无患者出现严重并发症。结论:经经验丰富的外科医生采用逆行输尿管软镜联合微型经皮肾镜取石术治疗复杂肾结石是一种成功的技术,可以安全地进行俯卧劈腿位的内镜联合肾内手术。
{"title":"The efficacy and safety of one-stage endoscopy combined with intrarenal surgery (mini-nephrostomy tract) in the prone split-leg position for complex renal calculi.","authors":"Kai Yu,&nbsp;Zhebin Du,&nbsp;Hanqing Xuan,&nbsp;Yang Cao,&nbsp;Hai Zhong,&nbsp;Fangzhou Li,&nbsp;Qi Chen","doi":"10.1097/CU9.0000000000000148","DOIUrl":"https://doi.org/10.1097/CU9.0000000000000148","url":null,"abstract":"<p><strong>Background: </strong>The goal of this study was to determine the safety and efficacy of endoscopic combined intrarenal surgery (ECIRS) performed in the prone split-leg position for the treatment of complex renal stones.</p><p><strong>Materials and methods: </strong>A mature ECIRS protocol was designed. Retrospective analysis was conducted of medical records between January 2020 and December 2021 of patients with complex renal stones at one center who underwent ECIRS by 2 skilled surgeons using retrograde flexible ureteroscopy and mini-percutaneous nephrolithotomy in the prone split-leg position.</p><p><strong>Results: </strong>A total of 44 patients were included in this study. Mean stone size was 26.1 ± 12.7 mm, and the number of calyces involved was 4.36 ± 2.09. Mean operative time was 71.1 ± 21.8 minutes. Postoperative decline in hemoglobin was 15.8 ± 9.8 g/L. Seventy-five percent of patients achieved stone-free status. The mean number of residual stones was 2.8 ± 2.3, and the mean residual stone size was 10.30 ± 4.76 mm. Six patients (13.6%) developed postoperative complications, including 4 with fever during the first 2 days postoperatively and 2 patients with transient postoperative pain. No patients developed severe complications.</p><p><strong>Conclusions: </strong>Endoscopic combined intrarenal surgery in the prone split-leg position can be performed safely by experienced surgeons using retrograde flexible ureteroscopy in conjunction with mini-percutaneous nephrolithotomy as a successful technique for the treatment of complex renal stones.</p>","PeriodicalId":39147,"journal":{"name":"Current Urology","volume":"17 1","pages":"13-17"},"PeriodicalIF":1.6,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/00/a6/curr-urol-17-13.PMC10487290.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10221803","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Significance of timing of therapeutic line on effectiveness of nivolumab for metastatic renal cell carcinoma. 纳武单抗治疗转移性肾细胞癌疗效的临床意义。
IF 1.6 4区 医学 Q4 UROLOGY & NEPHROLOGY Pub Date : 2023-03-01 DOI: 10.1097/CU9.0000000000000105
Jun Teishima, Daiki Murata, Kazuma Yukihiro, Yohei Sekino, Shogo Inoue, Tetsutaro Hayashi, Koji Mita, Yasuhisa Hasegawa, Masao Kato, Mitsuru Kajiwara, Masanobu Shigeta, Satoshi Maruyama, Hiroyuki Moriyama, Seiji Fujiwara, Akio Matsubara

Objectives: This study aimed to clarify the significance of therapeutic timing on the effectiveness of nivolumab for treating metastatic renal cell carcinoma.

Marterials and methods: Fifty-eight patients with metastatic renal cell carcinoma treated with nivolumab monotherapy were retrospectively studied. Patients who were treated with nivolumab as second-line therapy were included in the second-line group, while the others were included in the later-line group. The clinicopathological characteristics, effects of nivolumab, and prognoses of these groups were compared.

Results: Twenty and thirty-eight patients were included in the second-line and later-line groups, respectively. There were no significant differences in the distribution of International Metastatic Renal Cell Carcinoma Database Consotium risk and other clinicopathological characteristics between the 2 groups. The proportion of patients whose objective best response was progressive disease in the second-line group was significantly lower than that in the later-line group (15% vs. 50%, p = 0.0090). The 50% progression-free survival with nivolumab in the second-line group was significantly better than that in the later-line group (not reached and 5 months, p = 0.0018). Multivariate analysis showed that the second-line setting was an independent predictive factor for better progression-free survival (p = 0.0028, hazard ratio = 0.108). The 50% overall survival after starting nivolumab in the second-line and later-line groups was not reached and 27.8 months, respectively (p = 0.2652).

Conclusions: The therapeutic efficacy of nivolumab as second-line therapy is expected to be better than that of later therapy.

目的:本研究旨在阐明治疗时间对纳武单抗治疗转移性肾细胞癌疗效的影响。材料与方法:对58例接受纳武单抗单药治疗的转移性肾细胞癌患者进行回顾性研究。接受纳武单抗作为二线治疗的患者被纳入二线组,而其他患者被纳入二线组。比较两组患者的临床病理特征、纳武单抗的疗效和预后。结果:二线组和后线组分别有28例和38例患者。两组患者的国际转移性肾癌数据库风险分布及其他临床病理特征均无显著差异。二线组客观最佳反应为进展性疾病的患者比例显著低于二线组(15% vs. 50%, p = 0.0090)。nivolumab二线组50%的无进展生存期显著优于二线组(未达到和5个月,p = 0.0018)。多因素分析显示,二线设置是更好的无进展生存的独立预测因素(p = 0.0028,风险比= 0.108)。二线组和后线组纳武单抗启动后的总生存期分别为50%和27.8个月(p = 0.2652)。结论:纳武单抗作为二线治疗的疗效有望优于后续治疗。
{"title":"Significance of timing of therapeutic line on effectiveness of nivolumab for metastatic renal cell carcinoma.","authors":"Jun Teishima,&nbsp;Daiki Murata,&nbsp;Kazuma Yukihiro,&nbsp;Yohei Sekino,&nbsp;Shogo Inoue,&nbsp;Tetsutaro Hayashi,&nbsp;Koji Mita,&nbsp;Yasuhisa Hasegawa,&nbsp;Masao Kato,&nbsp;Mitsuru Kajiwara,&nbsp;Masanobu Shigeta,&nbsp;Satoshi Maruyama,&nbsp;Hiroyuki Moriyama,&nbsp;Seiji Fujiwara,&nbsp;Akio Matsubara","doi":"10.1097/CU9.0000000000000105","DOIUrl":"https://doi.org/10.1097/CU9.0000000000000105","url":null,"abstract":"<p><strong>Objectives: </strong>This study aimed to clarify the significance of therapeutic timing on the effectiveness of nivolumab for treating metastatic renal cell carcinoma.</p><p><strong>Marterials and methods: </strong>Fifty-eight patients with metastatic renal cell carcinoma treated with nivolumab monotherapy were retrospectively studied. Patients who were treated with nivolumab as second-line therapy were included in the second-line group, while the others were included in the later-line group. The clinicopathological characteristics, effects of nivolumab, and prognoses of these groups were compared.</p><p><strong>Results: </strong>Twenty and thirty-eight patients were included in the second-line and later-line groups, respectively. There were no significant differences in the distribution of International Metastatic Renal Cell Carcinoma Database Consotium risk and other clinicopathological characteristics between the 2 groups. The proportion of patients whose objective best response was progressive disease in the second-line group was significantly lower than that in the later-line group (15% vs. 50%, <i>p</i> = 0.0090). The 50% progression-free survival with nivolumab in the second-line group was significantly better than that in the later-line group (not reached and 5 months, <i>p</i> = 0.0018). Multivariate analysis showed that the second-line setting was an independent predictive factor for better progression-free survival (<i>p</i> = 0.0028, hazard ratio = 0.108). The 50% overall survival after starting nivolumab in the second-line and later-line groups was not reached and 27.8 months, respectively (<i>p</i> = 0.2652).</p><p><strong>Conclusions: </strong>The therapeutic efficacy of nivolumab as second-line therapy is expected to be better than that of later therapy.</p>","PeriodicalId":39147,"journal":{"name":"Current Urology","volume":"17 1","pages":"52-57"},"PeriodicalIF":1.6,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/32/95/curr-urol-17-52.PMC10487289.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10224050","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Metabolic evaluation of first-time uncomplicated renal stone formers: A prospective study. 首次无并发症肾结石患者的代谢评价:一项前瞻性研究。
IF 1.6 4区 医学 Q4 UROLOGY & NEPHROLOGY Pub Date : 2023-03-01 DOI: 10.1097/CU9.0000000000000169
Satish Kumar Ranjan, Ankur Mittal, Anissa Atif Mirza, Sunil Kumar, Vikas Kumar Panwar, Shivcharan Navriya, Arup Kumar Mandal, Kim Jacob Mammen

Background: Nephrolithiasis is a global health problem. The recurrence rate after the first stone clearance is approximately 50% at 5 years. Metabolic abnormalities are an important factor responsible for stone recurrence. Our prevalidated study aimed to evaluate metabolic abnormalities associated with first-time uncomplicated renal stone formers (FTURSF).

Materials and methods: In this prospective, exploratory, time-bound, descriptive study, 30 first-time renal stone formers were evaluated for metabolic abnormalities. High-risk stone formers were excluded from the study. Data were collected in a predefined proforma, transferred to an Excel sheet, and analyzed using the Statistical Package for Social Sciences 20 and Epi Info 7. Fisher exact test, Mann-Whitney U test, paired t test, and Pearson correlation coefficient were used for statistical analyses.

Results: The mean age of the participants was 35.57 ± 11.07 years, with a male-to-female ratio of 1.72. The most common abnormality was a 24-hour urine volume of <2.5 L in 73.33% of the participants. One or more metabolic abnormalities were detected in 76.67% of the participants. Other common metabolic abnormalities detected were hypocitraturia (60%), hypercalciuria (16.67%), hyperoxaluria (13.33%), and hyperuricosuria (3.33%). Parathyroid adenoma was detected in one participant (3.33%).

Conclusions: Our study documented significant metabolic abnormalities in FTURSF. Therefore, a simplified metabolic evaluation protocol should be adopted while evaluating FTURSF. Detection of an underlying metabolic abnormality would enable the early institution of preventive measures to reduce stone recurrence and related complications.

背景:肾结石是一个全球性的健康问题。第一次结石清除后5年复发率约为50%。代谢异常是导致结石复发的重要因素。我们的预验证研究旨在评估与首次无并发症肾结石(FTURSF)相关的代谢异常。材料和方法:在这项前瞻性、探索性、时限性、描述性研究中,对30例首次肾结石患者进行代谢异常评估。高危结石患者被排除在研究之外。数据以预定义的形式收集,转移到Excel表格,并使用社会科学统计软件包20和Epi信息7进行分析。采用Fisher精确检验、Mann-Whitney U检验、配对t检验和Pearson相关系数进行统计分析。结果:参与者平均年龄为35.57±11.07岁,男女性别比为1.72。最常见的异常是24小时尿量。结论:我们的研究记录了FTURSF显著的代谢异常。因此,在评价FTURSF时应采用简化的代谢评价方案。发现潜在的代谢异常将有助于早期采取预防措施,以减少结石复发和相关并发症。
{"title":"Metabolic evaluation of first-time uncomplicated renal stone formers: A prospective study.","authors":"Satish Kumar Ranjan,&nbsp;Ankur Mittal,&nbsp;Anissa Atif Mirza,&nbsp;Sunil Kumar,&nbsp;Vikas Kumar Panwar,&nbsp;Shivcharan Navriya,&nbsp;Arup Kumar Mandal,&nbsp;Kim Jacob Mammen","doi":"10.1097/CU9.0000000000000169","DOIUrl":"https://doi.org/10.1097/CU9.0000000000000169","url":null,"abstract":"<p><strong>Background: </strong>Nephrolithiasis is a global health problem. The recurrence rate after the first stone clearance is approximately 50% at 5 years. Metabolic abnormalities are an important factor responsible for stone recurrence. Our prevalidated study aimed to evaluate metabolic abnormalities associated with first-time uncomplicated renal stone formers (FTURSF).</p><p><strong>Materials and methods: </strong>In this prospective, exploratory, time-bound, descriptive study, 30 first-time renal stone formers were evaluated for metabolic abnormalities. High-risk stone formers were excluded from the study. Data were collected in a predefined proforma, transferred to an Excel sheet, and analyzed using the Statistical Package for Social Sciences 20 and Epi Info 7. Fisher exact test, Mann-Whitney <i>U</i> test, paired <i>t</i> test, and Pearson correlation coefficient were used for statistical analyses.</p><p><strong>Results: </strong>The mean age of the participants was 35.57 ± 11.07 years, with a male-to-female ratio of 1.72. The most common abnormality was a 24-hour urine volume of <2.5 L in 73.33% of the participants. One or more metabolic abnormalities were detected in 76.67% of the participants. Other common metabolic abnormalities detected were hypocitraturia (60%), hypercalciuria (16.67%), hyperoxaluria (13.33%), and hyperuricosuria (3.33%). Parathyroid adenoma was detected in one participant (3.33%).</p><p><strong>Conclusions: </strong>Our study documented significant metabolic abnormalities in FTURSF. Therefore, a simplified metabolic evaluation protocol should be adopted while evaluating FTURSF. Detection of an underlying metabolic abnormality would enable the early institution of preventive measures to reduce stone recurrence and related complications.</p>","PeriodicalId":39147,"journal":{"name":"Current Urology","volume":"17 1","pages":"36-40"},"PeriodicalIF":1.6,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/fb/df/curr-urol-17-36.PMC10487292.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10275563","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effects of lemon-tomato juice consumption on crystal formation in the urine of patients with calcium oxalate stones: A randomized crossover clinical trial. 柠檬番茄汁对草酸钙结石患者尿液晶体形成的影响:一项随机交叉临床试验。
IF 1.6 4区 医学 Q4 UROLOGY & NEPHROLOGY Pub Date : 2023-03-01 DOI: 10.1097/CU9.0000000000000178
Sathish K Gopala, Jim Joe, Jithesh Chandran

Background: Dietary supplementation with citrate-containing juices may serve as an effective alternative to potassium citrate therapy for preventing calcium oxalate stone recurrence. This study was performed to evaluate whether consumption of lemon-tomato juice can decrease the tendency for stone formation in the urine of calcium oxalate stone formers.

Materials and methods: The study was conducted as a prospective interventional randomized crossover clinical trial with a repeated-measures design. Twenty-two patients with calcium oxalate stones and no metabolic abnormalities in the urine treated with lithotripsy at a tertiary care center from August 2017 to July 2018 were recruited. After a 14-hour overnight fasting, urine samples were collected after the patients consumed either milk only or milk and lemon-tomato juice. Their urine was tested for multiple parameters, including urine pH, specific gravity, calcium-creatinine ratio, and supersaturation with sodium oxalate, followed by optical density measurement via spectrophotometry.

Results: There were no significant differences in the background characteristics between the 2 groups. The optical density of the urine samples obtained after consumption of milk only was significantly higher than that after consumption of milk and lemon-tomato juice (mean = 0.131 for milk only vs. 0.053 for milk and lemon-tomato juice, p < 0.001). The urine calcium-creatinine ratio was similar between the groups (mean = 0.141 for milk only vs. 0.076 for milk and lemon-tomato juice, p = 0.019).

Conclusions: The addition of lemon-tomato juice as a source of citrate in the diet significantly decreases the established risk factors for calcium oxalate stone formation in patients. This study was prospectively registered at CTRI under number CTRI/2017/04/008312 on April 7, 2017.

背景:饮食补充含有柠檬酸盐的果汁可能是预防草酸钙结石复发的有效替代柠檬酸钾疗法。本研究旨在评估饮用柠檬番茄汁是否能降低草酸钙结石患者尿液中结石形成的趋势。材料与方法:本研究为前瞻性介入随机交叉临床试验,采用重复测量设计。研究招募了2017年8月至2018年7月在某三级保健中心接受碎石治疗的22例草酸钙结石且尿液无代谢异常的患者。禁食14小时后,在患者只喝牛奶或牛奶加柠檬番茄汁后收集尿液样本。对他们的尿液进行多项参数测试,包括尿液pH值、比重、钙-肌酐比和草酸钠过饱和,然后通过分光光度法测量光密度。结果:两组患者背景特征差异无统计学意义。仅饮用牛奶后尿液的光密度显著高于饮用牛奶和柠檬番茄汁后尿液的光密度(仅饮用牛奶的平均值= 0.131,而牛奶和柠檬番茄汁的平均值为0.053,p < 0.001)。两组之间的尿钙-肌酐比值相似(仅牛奶组的平均值为0.141,而牛奶和柠檬番茄汁组的平均值为0.076,p = 0.019)。结论:在饮食中添加柠檬番茄汁作为柠檬酸盐的来源,可显著降低患者草酸钙结石形成的既定危险因素。本研究已于2017年4月7日在CTRI注册,注册号为CTRI/2017/04/008312。
{"title":"Effects of lemon-tomato juice consumption on crystal formation in the urine of patients with calcium oxalate stones: A randomized crossover clinical trial.","authors":"Sathish K Gopala,&nbsp;Jim Joe,&nbsp;Jithesh Chandran","doi":"10.1097/CU9.0000000000000178","DOIUrl":"https://doi.org/10.1097/CU9.0000000000000178","url":null,"abstract":"<p><strong>Background: </strong>Dietary supplementation with citrate-containing juices may serve as an effective alternative to potassium citrate therapy for preventing calcium oxalate stone recurrence. This study was performed to evaluate whether consumption of lemon-tomato juice can decrease the tendency for stone formation in the urine of calcium oxalate stone formers.</p><p><strong>Materials and methods: </strong>The study was conducted as a prospective interventional randomized crossover clinical trial with a repeated-measures design. Twenty-two patients with calcium oxalate stones and no metabolic abnormalities in the urine treated with lithotripsy at a tertiary care center from August 2017 to July 2018 were recruited. After a 14-hour overnight fasting, urine samples were collected after the patients consumed either milk only or milk and lemon-tomato juice. Their urine was tested for multiple parameters, including urine pH, specific gravity, calcium-creatinine ratio, and supersaturation with sodium oxalate, followed by optical density measurement via spectrophotometry.</p><p><strong>Results: </strong>There were no significant differences in the background characteristics between the 2 groups. The optical density of the urine samples obtained after consumption of milk only was significantly higher than that after consumption of milk and lemon-tomato juice (mean = 0.131 for milk only vs. 0.053 for milk and lemon-tomato juice, <i>p</i> < 0.001). The urine calcium-creatinine ratio was similar between the groups (mean = 0.141 for milk only vs. 0.076 for milk and lemon-tomato juice, <i>p</i> = 0.019).</p><p><strong>Conclusions: </strong>The addition of lemon-tomato juice as a source of citrate in the diet significantly decreases the established risk factors for calcium oxalate stone formation in patients. This study was prospectively registered at CTRI under number CTRI/2017/04/008312 on April 7, 2017.</p>","PeriodicalId":39147,"journal":{"name":"Current Urology","volume":"17 1","pages":"25-29"},"PeriodicalIF":1.6,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/76/db/curr-urol-17-25.PMC10487295.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10275567","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Assessment of the efficacy of reduced-radiation noncontrast computed tomography scan compared with the standard noncontrast computed tomography scan for detecting urolithiasis: A prospective single-center study. 评估低辐射非对比计算机断层扫描与标准非对比计算机断层扫描检测尿石症的疗效:一项前瞻性单中心研究。
IF 1.6 4区 医学 Q4 UROLOGY & NEPHROLOGY Pub Date : 2023-03-01 DOI: 10.1097/CU9.0000000000000162
Gaurav Aggarwal, Samiran Das Adhikary

Background: Noncontrast computed tomography (CT) scan of the kidneys, ureter and bladder is the standard investigative modality for diagnosing and following up patients with urolithiasis. With each scan, a patient receives radiation of 18-34 mGy. Dose considerations become pertinent because of a 10% lifetime incidence rate and higher than 50% risk of recurrence, necessitating repeated imaging in the lifetime of a stone former. Hence, this study aimed to assess the sensitivity of "reduced-radiation" CT imaging by altering scan settings to lower than the "standard" norms.

Materials and methods: Altogether, 222 patients (255 "kidney-ureter" stone-bearing units or "renal units") with urolithiasis and patients undergoing CT for other reasons with incidental findings of renal/ureteric calculi between 2017 and 2019 were included. All patients were subjected to 3 sequential scans at tube current settings of 250 mA (CT-N/Standard), 100 mA (CT-100), and 50 mA (CT-50) at a constant voltage of 120 kV. Their clinicodemographic and radiological findings were recorded and assessed for significance.

Results: Of the 255 renal units, 117 were between 30 and 44 years of age, 75% were men. Of the 255 patients, 178 (70.1%) reported a first stone episode and 77 had recurrence. Lower ureteric calculi were predominant (40.4%). All calculi were identified on CT-N; CT-100 failed to detect calculi in 1 patient, and CT-50 failed in 3 patients, where all calculi were <3 mm in size. Meanwhile, none were undetected among patients with obesity. The sensitivity was 99.61% for the CT-100 and 98.82% for the CT-50, which indicated a 2.5 and 5 times lower radiation and dose/length, respectively, than CT-N.

Conclusions: The reduced-radiation CT scan is safe, sensitive, and accurate for the diagnosis and follow-up of patients with urolithiasis with significantly lower radiation exposures. Our study lays the foundation to accept low-dose CT in general and CT-50 in particular, as the new "standard of care," and attempt further dose reduction without loss of diagnostic efficacy.

背景:肾脏、输尿管和膀胱的CT扫描是诊断和随访尿石症患者的标准检查方式。每次扫描,患者接受18-34毫戈瑞的辐射。由于终生发病率为10%,复发率高于50%,剂量考虑变得相关,因此需要在结石成形术患者的一生中反复进行影像学检查。因此,本研究旨在通过改变扫描设置以低于“标准”规范来评估“降低辐射”CT成像的敏感性。材料和方法:2017年至2019年共纳入222例尿石症患者(255例“肾-输尿管”结石或“肾单元”)和因其他原因接受CT检查的偶然发现肾/输尿管结石的患者。所有患者在管电流设置为250 mA (CT-N/Standard)、100 mA (CT-100)和50 mA (CT-50)、120 kV恒定电压下进行3次连续扫描。记录他们的临床人口学和放射学结果并评估其重要性。结果:255个肾单位中,年龄在30 - 44岁之间的117个,75%为男性。在255例患者中,178例(70.1%)报告首次结石发作,77例复发。输尿管下段结石以40.4%为主。所有结石均行CT-N检查;CT-100未检出结石1例,CT-50未检出结石3例,均为结石。结论:低辐射CT扫描对尿石症患者的诊断和随访安全、灵敏、准确,且辐射暴露明显降低。我们的研究为普遍接受低剂量CT,特别是CT-50作为新的“护理标准”,并在不丧失诊断效果的情况下尝试进一步减少剂量奠定了基础。
{"title":"Assessment of the efficacy of reduced-radiation noncontrast computed tomography scan compared with the standard noncontrast computed tomography scan for detecting urolithiasis: A prospective single-center study.","authors":"Gaurav Aggarwal,&nbsp;Samiran Das Adhikary","doi":"10.1097/CU9.0000000000000162","DOIUrl":"https://doi.org/10.1097/CU9.0000000000000162","url":null,"abstract":"<p><strong>Background: </strong>Noncontrast computed tomography (CT) scan of the kidneys, ureter and bladder is the standard investigative modality for diagnosing and following up patients with urolithiasis. With each scan, a patient receives radiation of 18-34 mGy. Dose considerations become pertinent because of a 10% lifetime incidence rate and higher than 50% risk of recurrence, necessitating repeated imaging in the lifetime of a stone former. Hence, this study aimed to assess the sensitivity of \"reduced-radiation\" CT imaging by altering scan settings to lower than the \"standard\" norms.</p><p><strong>Materials and methods: </strong>Altogether, 222 patients (255 \"kidney-ureter\" stone-bearing units or \"renal units\") with urolithiasis and patients undergoing CT for other reasons with incidental findings of renal/ureteric calculi between 2017 and 2019 were included. All patients were subjected to 3 sequential scans at tube current settings of 250 mA (CT-N/Standard), 100 mA (CT-100), and 50 mA (CT-50) at a constant voltage of 120 kV. Their clinicodemographic and radiological findings were recorded and assessed for significance.</p><p><strong>Results: </strong>Of the 255 renal units, 117 were between 30 and 44 years of age, 75% were men. Of the 255 patients, 178 (70.1%) reported a first stone episode and 77 had recurrence. Lower ureteric calculi were predominant (40.4%). All calculi were identified on CT-N; CT-100 failed to detect calculi in 1 patient, and CT-50 failed in 3 patients, where all calculi were <3 mm in size. Meanwhile, none were undetected among patients with obesity. The sensitivity was 99.61% for the CT-100 and 98.82% for the CT-50, which indicated a 2.5 and 5 times lower radiation and dose/length, respectively, than CT-N.</p><p><strong>Conclusions: </strong>The reduced-radiation CT scan is safe, sensitive, and accurate for the diagnosis and follow-up of patients with urolithiasis with significantly lower radiation exposures. Our study lays the foundation to accept low-dose CT in general and CT-50 in particular, as the new \"standard of care,\" and attempt further dose reduction without loss of diagnostic efficacy.</p>","PeriodicalId":39147,"journal":{"name":"Current Urology","volume":"17 1","pages":"18-24"},"PeriodicalIF":1.6,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/9c/d0/curr-urol-17-18.PMC10487294.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10224043","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Current Urology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1